Selected Quarterly Financial Data (Unaudited)

12 Months Ended

Dec. 31, 2012

Selected Quarterly Financial Data (Unaudited)

Selected Quarterly Financial Data (Unaudited)

22. Selected Quarterly Financial Data (Unaudited)

        The following table contains quarterly financial information for 2011 and 2012. The Company believes that the following information reflects all normal recurring adjustments necessary for a fair statement of the information for the periods presented. The operating results for any quarter are not necessarily indicative of results for any future period.

	First Quarter			Second Quarter			Third Quarter			Fourth Quarter
	(in thousands, except per share data)
2011
Collaboration revenues	$	6,461		$	6,595		$	8,582		$	12,577
Total operating expenses		21,102			36,019			27,219			30,744
Net loss		(13,535	)		(29,196	)		(18,724	)		(18,221	)
Net loss attributable to Merrimack Pharmaceuticals, Inc.		(13,457	)		(29,051	)		(18,599	)		(18,116	)
Net loss per share available to common stockholders—basic and diluted	$	(1.34	)	$	(2.76	)	$	(1.81	)	$	(1.76	)

	First Quarter			Second Quarter			Third Quarter			Fourth Quarter
	(in thousands, except per share data)
2012
Collaboration revenues	$	11,344		$	12,063		$	11,323		$	14,191
Total operating expenses		35,379			32,368			35,197			38,719
Net loss		(23,402	)		(20,139	)		(23,320	)		(24,893	)
Net loss attributable to Merrimack Pharmaceuticals, Inc.		(23,284	)		(20,026	)		(23,199	)		(24,768	)
Net loss per share available to common stockholders—basic and diluted	$	(2.14	)	$	(0.22	)	$	(0.25	)	$	(0.26	)